BB 203
Alternative Names: BB-203Latest Information Update: 29 Aug 2025
At a glance
- Originator Bright Biologics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 11 Aug 2025 BB 203 is available for licensing as of 11 Aug 2025. http://brightbiologicsllc.com/partnership.html
- 05 Nov 2024 Preclinical trials in Solid tumours in USA (Parenteral) before November 2024 (Bright Biologics pipeline, August 2025)
- 05 Nov 2024 Pharmacodynamics, pharmacokinetics and adverse events data from a Preclinical trial in Solid tumors released by Bright Biologics